About B-MoGen
B-MoGen is a Healthcare company based in Minneapolis (United States) founded in 2015, and was acquired by Bio-Techne in June 2019. Developer of solutions for gene editing and gene delivery. B-MoGen has raised $1.03 million across 5 funding rounds from investors including Bio-Techne and HHS. The company was acqui-hired. B-MoGen offers products and services including TcBuster, Recombinant Proteins, Antibodies, ELISAs, and Luminex Assays. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is R&D Systems, Inc. Its competitors include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
B-MoGen was founded in 2015 in Minneapolis, United States, within the biotechnology sector focused on genetic technologies. The Sleeping Beauty transposon system is utilized to create solutions that facilitate gene delivery in challenging cell types, such as primary cells. Enhancements to gene expression duration are provided, alongside services for custom vector production and targeted genome modifications. Operations emphasize practical applications in research and therapeutic development.
- Headquarters Minneapolis, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website bmogen.com
- Social LinkedIn X Facebook YouTube
- Acquired by Bio-Techne (Jun 2019)
- Legal Name R&D Systems, Inc.
- Total Equity Funding$1.03M (USD)
in 5 rounds
- Latest Funding Round$188.54K (USD), Grant
Aug 2018
- InvestorsBio-Techne
& 1 more
- Acquired byBio-Techne
(Jun 2019)
Products & Services of B-MoGen
B-MoGen offers a comprehensive portfolio of products and services, including TcBuster, Recombinant Proteins, Antibodies, ELISAs, and Luminex Assays.
Non-viral system for stable gene transfer in cell therapies
Proteins for biological assays and cell culture applications
Used in ELISAs and immunoassays for protein detection
Kits for measuring proteins in research and diagnostics
Platforms for simultaneous biomarker analysis in workflows
Apps and channels of B-MoGen
its YouTube channel Bio-Techne has 509 subscribers and 30 videos.
Videos from B-MoGen
The most watched videos on B-MoGen's YouTube channel, Bio-Techne (509 subscribers). Click a video to play it here.
More on Bio-Techne.
Funding Insights of B-MoGen
B-MoGen has successfully raised a total of $1.03M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $188.54 thousand completed in August 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.03M
- Total Rounds 5
- Last Round Grant — $188,543
- First Round $1.03M
(May 2016)
- Investors Count 2
All 5 funding rounds of B-MoGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2018 | $188,543 | Grant | – | – | |
| Aug 2018 | $1.62M | Grant | – | – | |
| Aug 2017 | $224,564 | Grant | – | – | |
| May 2017 | $224,634 | Grant | – | – | |
| May 2016 | $1.03M | Seed | – | – |
2 investors in total: 2 institutional.
Investors in B-MoGen
B-MoGen has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Bio-Techne and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Developer of biotech reagents, instruments and clinical diagnostic products | 1981 | bio-techne.com | Minneapolis, United States |
Investor details for B-MoGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of B-MoGen
4 dated milestones of B-MoGen across 4 years, from founding to its latest funding, stage changes and deals.
- Founded B-MoGen is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Grant, of $189K.
- Exit Acquired by Bio-Techne.
Competitors of B-MoGen
B-MoGen has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform |
Detailed competitors of B-MoGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as B-MoGen (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about B-Mogen
Complete news archive for B-MoGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about B-MoGen
B-MoGen was founded in 2015 and raised its 1st funding round 1 year after it was founded.
B-MoGen is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
B-MoGen is a funded company, having raised a total of $1.03M across 5 funding rounds to date. The company's 1st funding round was a Seed of $1.03M, raised on May 2016.
B-MoGen was founded in 2015 in Minneapolis, United States, within the biotechnology sector focused on genetic technologies. The Sleeping Beauty transposon system is utilized to create solutions that facilitate gene delivery in challenging cell types, such as primary cells. Enhancements to gene expression duration are provided, alongside services for custom vector production and targeted genome modifications. Operations emphasize practical applications in research and therapeutic development.
B-MoGen's top competitors include Sutro Biopharma, Avidity Biosciences and Vividion Therapeutics.
B-MoGen offers TcBuster, Recombinant Proteins, Antibodies, ELISAs, and Luminex Assays.
B-MoGen has 2 investors. Key investors include Bio-Techne, and HHS.
B-MoGen operates through R&D Systems, Inc..
Yes. B-MoGen was acquired by Bio-Techne in June 2019.